Search the Newsreel

Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired …

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.73 per share for the second quarter of 2026, missing the Zacks Consensus Estimate of $4.79. Earnings, however, rose around 4.6% year over year on higher product revenues. Second-quarter total revenues of $3.33 billion beat the Zacks …

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to …

Crinetics Reports Wider Q2 Loss; Withdraws Guidance Ahead Of Company's Acquisition

(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) reported a wider net loss for the second quarter ended June 30, 2026, and also provided various business highlights. The company recently began generating revenue with the commercial launch of PALSONIFY (Paltusotine) for acromegaly. Company Profile Crinetics Pharmaceuticals …

Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price …

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Revenue Growth Surges by 2,873% Amidst Strong Biotech Potential

Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M

Crinetics (Nasdaq: CRNX) agrees to $85 cash-per-share sale to Vertex

Crinetics Pharmaceuticals announced it has agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, totaling approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, pending regulatory …

Crinetics Pharmaceuticals GAAP EPS of -$1.14 beats by $0.07, revenue of $25.12M beats by $10.25M

* Crinetics Pharmaceuticals press release [https://seekingalpha.com/pr/20604770-crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business] (CRNX [https://seekingalpha.com/symbol/CRNX]): Q2 GAAP EPS of -$1.14 beats by $0.07. * Revenue of $25.12M (+2412.0% Y/Y) beats by $10.25M. * Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net …

Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M

Crinetics Pharmaceuticals, Inc. (CRNX) announced its Q2 revenue of $25.1 million, significantly exceeding the FactSet estimate of $14.8 million. The company is a clinical-stage pharmaceutical firm specializing in treatments for rare endocrine diseases and endocrine-related tumors, with lead candidates PALSONIFY and Atumelnant. This strong …

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals, Inc. Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- …

Canaccord raises Neurocrine Bio price target on strong sales beat

Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company …

Trading Systems Reacting to (CRNX) Volatility

This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide trading strategies. It notes a neutral near and mid-term outlook but a positive long-term bias, with no resistance levels above the current price suggesting upside potential. The report details position trading, momentum …

Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX)

Farallon Capital Management, L.L.C. has disclosed an 8.5% beneficial ownership stake in Crinetics Pharmaceuticals, Inc. (CRNX) through a Schedule 13G/A filing. As of June 30, 2026, Farallon holds 8,989,098 shares of Crinetics' common stock across several investment partnerships, with senior members Joshua J. Dapice …

H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com

H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Issues Earnings Results

Crinetics Pharmaceuticals (CRNX) Earnings Date and Reports 2026

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago. These figures are adjusted for non-recurring items. This …

Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price declined by about 10% on the day of the announcement, despite positive longer-term momentum. The stock is currently valued at $166.80, considered 13.5% undervalued by Simply …

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also …

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company …

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus

Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside

Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 …

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

Neurocrine Biosciences, Inc. NBIX highlighted the continued expansion of its commercial portfolio during its second-quarter 2026 earnings call, with management emphasizing growth from INGREZZA, CRENESSITY and the newly acquired VYKAT XR. The company also outlined upcoming clinical catalysts and its strategy to diversify beyond …

Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat

Guggenheim has increased its price target for Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares to $222 from $200, maintaining a Buy rating after the company's strong second-quarter results. The company reported Ingrezza sales significantly above consensus and raised its full-year 2026 Ingrezza sales guidance, driven by …

[10-Q] NEUROCRINE BIOSCIENCES INC Quarterly Earnings Report

Neurocrine Biosciences Inc. (NBIX) filed its quarterly earnings report (Form 10-Q) with the SEC, detailing its financial performance for the quarter ended June 30, 2026. Key highlights include the completion of the Soleno Therapeutics Inc. acquisition, adding VYKAT XR to its commercial portfolio, and …

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced …